Tawbi, H.-H., Burgess, M. A., Crowley, J., Van Tine, B. A., Hu, J., Schuetze, S., … Patel, S. (2016). Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. In Journal of Clinical Oncology (Vol. 34, pp. 11006–11006). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.11006

Tawbi, Hussein Abdul-Hassan, Melissa Amber Burgess, John Crowley, Brian Andrew Van Tine, James Hu, Scott Schuetze, Sandra P. D’Angelo, et al. “Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study.” In Journal of Clinical Oncology, 34:11006–11006. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.11006.

Tawbi HA-H, Burgess MA, Crowley J, Van Tine BA, Hu J, Schuetze S, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 11006–11006.

Tawbi, Hussein Abdul-Hassan, et al. “Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 11006–11006. Crossref, doi:10.1200/jco.2016.34.15_suppl.11006.

Tawbi HA-H, Burgess MA, Crowley J, Van Tine BA, Hu J, Schuetze S, D’Angelo SP, Attia S, Priebat DA, Okuno SH, Riedel RF, Davis LE, Movva S, Reed DR, Baker LH, Reinke DK, Maki RG, Patel S. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 11006–11006.